Progyny (PGNY) Expected to Announce Earnings on Tuesday

Progyny (NASDAQ:PGNY - Get Free Report) is expected to release its earnings data after the market closes on Tuesday, February 25th. Analysts expect Progyny to post earnings of $0.36 per share and revenue of $277.31 million for the quarter. Persons interested in participating in the company's earnings conference call can do so using this link.

Progyny Stock Down 2.8 %

NASDAQ:PGNY traded down $0.68 on Friday, reaching $23.20. The company's stock had a trading volume of 1,243,035 shares, compared to its average volume of 1,799,572. Progyny has a 12-month low of $13.39 and a 12-month high of $40.89. The firm has a market cap of $1.98 billion, a price-to-earnings ratio of 40.00, a price-to-earnings-growth ratio of 2.37 and a beta of 1.34. The stock has a 50 day moving average price of $19.84 and a 200 day moving average price of $18.66.

Analyst Upgrades and Downgrades

A number of research firms have commented on PGNY. Canaccord Genuity Group reduced their target price on Progyny from $18.00 to $17.00 and set a "hold" rating on the stock in a research report on Wednesday, November 13th. Truist Financial reiterated a "hold" rating and issued a $19.00 price objective (down previously from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Barclays cut their price objective on Progyny from $30.00 to $17.00 and set an "overweight" rating on the stock in a report on Thursday, November 14th. JPMorgan Chase & Co. boosted their price objective on Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Finally, Bank of America boosted their price objective on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, February 11th. Nine equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Progyny currently has a consensus rating of "Hold" and an average price target of $25.83.

Insider Buying and Selling

In other Progyny news, CEO Peter Anevski acquired 209,500 shares of the stock in a transaction dated Monday, December 23rd. The stock was acquired at an average cost of $14.48 per share, with a total value of $3,033,560.00. Following the transaction, the chief executive officer now owns 441,463 shares in the company, valued at $6,392,384.24. The trade was a 90.32 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman David J. Schlanger acquired 150,000 shares of the stock in a transaction dated Thursday, December 26th. The shares were acquired at an average cost of $14.68 per share, with a total value of $2,202,000.00. Following the completion of the transaction, the chairman now owns 228,269 shares in the company, valued at approximately $3,350,988.92. This represents a 191.65 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by insiders.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.